0114 Cancer Early Detection Roundup
BioCentury & Getty Images

Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

How two new early cancer detection companies aim to stand out from the pack

How two new early cancer detection companies aim to stand out from the pack. 

Jan 15, 2021 | 12:40 AM GMT

The debut of two more venture-backed companies developing early cancer detection tests suggests there is still appetite for new approaches, even as bigger players consolidate via M&A and prepare for commercial launch.

Delfi Diagnostics Inc. raised an OrbiMed-led $100 million series A round to develop a test based on fragmentation patterns in plasma cell-free DNA (cfDNA), while Earli Inc. raised $40 million in support of its “synthetic biopsy”

Read the full 1255 word article

How to gain access

Continue reading with a
two-week free trial.